Previous 10 | Next 10 |
2023-11-17 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-07 10:08:44 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...
2023-11-07 09:47:25 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials. Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected appro...
2023-11-06 10:11:02 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024. Top-line results for on-going, 76-week Phase 3 trial expected approximately ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Cassava Sciences Inc. (SAVA) is expected to report $-0.9 for Q3 2023
2023-11-03 03:55:48 ET Summary Cassava Sciences' presentation at the CTAD Conference undermines its claim that simufilam is an effective treatment for Alzheimer's Disease. The drug appears to have little to no effect on moderate Alzheimer's disease and only better for a year than ...
2023-10-30 03:30:35 ET Summary Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating ...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...